Safety and efficacy of the conversion of Immediate- Release Topiramate to Extended-Release Topiramate (Trokendi XR®) fluency and patient satisfaction in patients with chronic migraine

Trial Profile

Safety and efficacy of the conversion of Immediate- Release Topiramate to Extended-Release Topiramate (Trokendi XR®) fluency and patient satisfaction in patients with chronic migraine

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Topiramate (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jun 2017 Results presented at the 59th Annual Scientific Meeting of the American Headache Society
    • 08 May 2017 New trial record
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top